Financial Ratios Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Equities
002223
CNE1000009X3
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.27 CNY | -0.08% |
|
-4.83% | -5.08% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 13.93 | 8.44 | 6.4 | 8.15 | 5.59 | |||||
Return on Total Capital | 17.39 | 10.3 | 7.84 | 9.99 | 6.84 | |||||
Return On Equity % | 25.74 | 18.64 | 17.01 | 21.62 | 14.69 | |||||
Return on Common Equity | 26.04 | 18.87 | 17.59 | 22.16 | 14.86 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 52.59 | 47.99 | 47.77 | 51 | 49.83 | |||||
SG&A Margin | 16.56 | 19.34 | 20.44 | 18.93 | 23.65 | |||||
EBITDA Margin % | 32.23 | 24.25 | 22.31 | 27.97 | 21.48 | |||||
EBITA Margin % | 30.1 | 21.86 | 19.93 | 25.72 | 19.01 | |||||
EBIT Margin % | 29.87 | 21.61 | 19.53 | 25.4 | 18.7 | |||||
Income From Continuing Operations Margin % | 26.12 | 21.53 | 22.15 | 29.81 | 23.85 | |||||
Net Income Margin % | 26.15 | 21.5 | 22.46 | 30.05 | 23.87 | |||||
Net Avail. For Common Margin % | 26.15 | 21.5 | 22.46 | 30.05 | 23.87 | |||||
Normalized Net Income Margin | 18.7 | 14.61 | 14.5 | 18.48 | 13.85 | |||||
Levered Free Cash Flow Margin | 25.25 | 10.86 | 17.67 | 18.39 | 12.15 | |||||
Unlevered Free Cash Flow Margin | 25.39 | 11.14 | 18.18 | 18.85 | 12.32 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.75 | 0.62 | 0.52 | 0.51 | 0.48 | |||||
Fixed Assets Turnover | 3.71 | 3.57 | 3.4 | 3.7 | 3.65 | |||||
Receivables Turnover (Average Receivables) | 6.41 | 8.32 | 9.47 | 12.82 | 10.95 | |||||
Inventory Turnover (Average Inventory) | 3.37 | 3.21 | 2.67 | 2.67 | 2.66 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.29 | 3.75 | 3.1 | 3.27 | 3.44 | |||||
Quick Ratio | 1.83 | 3.02 | 2.55 | 2.74 | 2.84 | |||||
Operating Cash Flow to Current Liabilities | 1.22 | 0.66 | 0.72 | 0.74 | 0.67 | |||||
Days Sales Outstanding (Average Receivables) | 57.08 | 43.86 | 38.53 | 28.46 | 33.42 | |||||
Days Outstanding Inventory (Average Inventory) | 108.72 | 113.69 | 136.51 | 136.49 | 137.53 | |||||
Average Days Payable Outstanding | 105.86 | 89.43 | 111.89 | 136.93 | 140.72 | |||||
Cash Conversion Cycle (Average Days) | 59.94 | 68.12 | 63.15 | 28.02 | 30.22 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 8.55 | 17.99 | 21 | 10.4 | 0.34 | |||||
Total Debt / Total Capital | 7.87 | 15.25 | 17.36 | 9.42 | 0.34 | |||||
LT Debt/Equity | - | 17.5 | 15.3 | 5.98 | 0.16 | |||||
Long-Term Debt / Total Capital | - | 14.83 | 12.64 | 5.42 | 0.16 | |||||
Total Liabilities / Total Assets | 25.54 | 29.74 | 33.31 | 25.38 | 19.12 | |||||
EBIT / Interest Expense | 131.76 | 48.87 | 24.02 | 34.59 | 68.25 | |||||
EBITDA / Interest Expense | 142.18 | 55.33 | 27.84 | 38.51 | 80.31 | |||||
(EBITDA - Capex) / Interest Expense | 97.65 | 46.01 | 21.27 | 36.25 | 74.12 | |||||
Total Debt / EBITDA | 0.3 | 0.9 | 1.31 | 0.55 | 0.03 | |||||
Net Debt / EBITDA | -1.27 | -1.87 | -3.26 | -2.65 | -3.95 | |||||
Total Debt / (EBITDA - Capex) | 0.43 | 1.08 | 1.72 | 0.58 | 0.03 | |||||
Net Debt / (EBITDA - Capex) | -1.85 | -2.25 | -4.26 | -2.82 | -4.28 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 45.08 | 2.51 | 3.01 | 12.25 | -5.09 | |||||
Gross Profit, 1 Yr. Growth % | 81.16 | -6.46 | 2.54 | 19.85 | -7.03 | |||||
EBITDA, 1 Yr. Growth % | 143.36 | -22.95 | -5.54 | 40.58 | -27.3 | |||||
EBITA, 1 Yr. Growth % | 148.66 | -25.63 | -6.43 | 44.66 | -30.02 | |||||
EBIT, 1 Yr. Growth % | 152.85 | -25.82 | -6.92 | 45.99 | -30.26 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 130.65 | -15.52 | 5.97 | 51.11 | -24.08 | |||||
Net Income, 1 Yr. Growth % | 133.74 | -15.73 | 7.6 | 50.21 | -24.63 | |||||
Normalized Net Income, 1 Yr. Growth % | 147.16 | -19.88 | 2.24 | 42.98 | -28.99 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 133.33 | -14.86 | 8.05 | 49.69 | -24.9 | |||||
Accounts Receivable, 1 Yr. Growth % | -33.06 | -3.08 | -10.51 | -23.92 | 57.43 | |||||
Inventory, 1 Yr. Growth % | 4.57 | 30.68 | 19.24 | -6.41 | 1.98 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 5.34 | 7.66 | 8.33 | -1.52 | -6.34 | |||||
Total Assets, 1 Yr. Growth % | 26.36 | 19.2 | 25.82 | 5.78 | -2.01 | |||||
Tangible Book Value, 1 Yr. Growth % | 28.07 | 7.38 | 26.14 | 23.27 | 8.02 | |||||
Common Equity, 1 Yr. Growth % | 22.51 | 11.22 | 19.2 | 19.31 | 6.56 | |||||
Cash From Operations, 1 Yr. Growth % | 360.9 | -57.57 | 91.88 | -7.72 | -14.61 | |||||
Capital Expenditures, 1 Yr. Growth % | 54.16 | -58.12 | 33.43 | -65.05 | -3.13 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 551.83 | -55.9 | 73.01 | 21.71 | -36.47 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 542.86 | -55.03 | 73.43 | 21.12 | -37.16 | |||||
Dividend Per Share, 1 Yr. Growth % | -25 | 0 | 100 | 33.33 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 26.8 | 21.95 | 2.76 | 7.53 | 3.22 | |||||
Gross Profit, 2 Yr. CAGR % | 45.71 | 30.17 | -2.06 | 10.86 | 5.42 | |||||
EBITDA, 2 Yr. CAGR % | 64.14 | 37 | -14.55 | 15.3 | 1.23 | |||||
EBITA, 2 Yr. CAGR % | 65.98 | 36.06 | -16.43 | 16.42 | 0.75 | |||||
EBIT, 2 Yr. CAGR % | 67.75 | 36.95 | -16.9 | 16.57 | 0.99 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 52.95 | 39.59 | -5.38 | 26.55 | 7.11 | |||||
Net Income, 2 Yr. CAGR % | 55.53 | 40.35 | -4.78 | 27.13 | 6.4 | |||||
Normalized Net Income, 2 Yr. CAGR % | 64.67 | 40.72 | -9.49 | 20.91 | 0.85 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 54.83 | 40.95 | -4.08 | 27.18 | 6.03 | |||||
Accounts Receivable, 2 Yr. CAGR % | -18.09 | -19.45 | -8.28 | -17.49 | 9.44 | |||||
Inventory, 2 Yr. CAGR % | 21.6 | 16.9 | 24.83 | 5.64 | -2.3 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 26.44 | 6.49 | 7.99 | 3.29 | -3.96 | |||||
Total Assets, 2 Yr. CAGR % | 20.68 | 22.73 | 22.46 | 15.36 | 1.81 | |||||
Tangible Book Value, 2 Yr. CAGR % | 21.29 | 17.27 | 16.38 | 24.7 | 15.39 | |||||
Common Equity, 2 Yr. CAGR % | 16.62 | 16.73 | 15.14 | 19.25 | 12.75 | |||||
Cash From Operations, 2 Yr. CAGR % | 88.33 | 39.85 | -9.77 | 33.07 | -11.23 | |||||
Capital Expenditures, 2 Yr. CAGR % | 32.02 | -19.65 | -25.25 | -31.72 | -41.82 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 149.77 | 69.54 | -14.03 | 42.16 | -12.63 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 149.44 | 70.02 | -13.05 | 42.07 | -13.31 | |||||
Dividend Per Share, 2 Yr. CAGR % | 41.42 | -13.4 | 41.42 | 63.3 | 15.47 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 23.84 | 18.12 | 15.28 | 5.83 | 3.15 | |||||
Gross Profit, 3 Yr. CAGR % | 36.23 | 25.7 | 20.22 | 4.76 | 4.45 | |||||
EBITDA, 3 Yr. CAGR % | 44.41 | 27.61 | 21.17 | 0.91 | -1.04 | |||||
EBITA, 3 Yr. CAGR % | 45.75 | 27.05 | 20.24 | 0.38 | -1.66 | |||||
EBIT, 3 Yr. CAGR % | 46.45 | 27.8 | 20.41 | 0.27 | -1.71 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 40.93 | 25.49 | 27.34 | 10.6 | 6.73 | |||||
Net Income, 3 Yr. CAGR % | 43.76 | 26.8 | 28.45 | 10.85 | 6.8 | |||||
Normalized Net Income, 3 Yr. CAGR % | 48.05 | 29.52 | 26.51 | 5.41 | 1.31 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 43.68 | 26.85 | 29 | 11.26 | 6.7 | |||||
Accounts Receivable, 3 Yr. CAGR % | -7.73 | -13.36 | -17.42 | -13.82 | 2.34 | |||||
Inventory, 3 Yr. CAGR % | 15.26 | 24.55 | 17.67 | 13.4 | 4.4 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 28.29 | 19.84 | 7.1 | 4.73 | -0.02 | |||||
Total Assets, 3 Yr. CAGR % | 14.94 | 20.18 | 23.75 | 16.63 | 9.25 | |||||
Tangible Book Value, 3 Yr. CAGR % | 16.08 | 16.46 | 20.15 | 18.63 | 18.87 | |||||
Common Equity, 3 Yr. CAGR % | 12.37 | 14.8 | 17.55 | 16.51 | 14.86 | |||||
Cash From Operations, 3 Yr. CAGR % | 126.97 | 14.6 | 55.4 | -9.09 | 14.78 | |||||
Capital Expenditures, 3 Yr. CAGR % | 11.48 | -9.96 | -4.85 | -41.98 | -23.27 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 41.37 | 40.12 | 68.89 | -4.78 | 8.22 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 41.9 | 40.91 | 69.39 | -4.17 | 7.79 | |||||
Dividend Per Share, 3 Yr. CAGR % | 25.99 | 25.99 | 14.47 | 38.67 | 38.67 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 26.17 | 21.16 | 14.93 | 13.76 | 10.29 | |||||
Gross Profit, 5 Yr. CAGR % | 33.42 | 26.55 | 19.39 | 19.54 | 14.07 | |||||
EBITDA, 5 Yr. CAGR % | 38.3 | 24.36 | 17.09 | 22.62 | 12.78 | |||||
EBITA, 5 Yr. CAGR % | 39.49 | 24.2 | 16.7 | 22.77 | 12.06 | |||||
EBIT, 5 Yr. CAGR % | 39.82 | 24.42 | 16.74 | 23.18 | 12.23 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 36.8 | 24.25 | 20.17 | 25.91 | 18.83 | |||||
Net Income, 5 Yr. CAGR % | 37.01 | 24.29 | 21.92 | 26.93 | 19.13 | |||||
Normalized Net Income, 5 Yr. CAGR % | 39.08 | 23.74 | 21.6 | 26 | 15.54 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 33.46 | 22.97 | 22.23 | 26.98 | 19.27 | |||||
Accounts Receivable, 5 Yr. CAGR % | 2.08 | 0.44 | -7.95 | -15.55 | -7.57 | |||||
Inventory, 5 Yr. CAGR % | 19.17 | 26.86 | 18.99 | 16.61 | 9.23 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 32.08 | 31.23 | 19.75 | 12.92 | 2.53 | |||||
Total Assets, 5 Yr. CAGR % | 28.03 | 15.59 | 17.89 | 18.23 | 14.45 | |||||
Tangible Book Value, 5 Yr. CAGR % | 30.34 | 8.08 | 16.2 | 19.69 | 18.23 | |||||
Common Equity, 5 Yr. CAGR % | 28.58 | 10.98 | 13.47 | 16.56 | 15.61 | |||||
Cash From Operations, 5 Yr. CAGR % | 39.12 | 12.24 | 56.94 | 21.66 | 24.21 | |||||
Capital Expenditures, 5 Yr. CAGR % | 32.72 | 30.08 | -4.99 | -19.39 | -21.84 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 57.56 | 13.42 | 15.86 | 40.04 | 28.69 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 56.49 | 13.72 | 16.66 | 40.5 | 28.55 | |||||
Dividend Per Share, 5 Yr. CAGR % | 2.38 | 2.38 | 31.95 | 39.77 | 14.87 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















